Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?
复制标题

DOI:
10.1007/s00125-009-1591-5
复制
发表时间:
2010-01
期刊:
影响因子:
8.2
通讯作者:
Elashoff, R.
Elashoff, R.
中科院分区:
医学1区
文献类型:
--
作者:
Butler, P. C.;Matveyenko, A. V.;Dry, S.;Bhushan, A.;Elashoff, R.

文献摘要

参考文献

被引文献

相似文献

在本期的《糖尿病学》杂志上,Nachnani和他的同事报告说,用胰高血糖素样肽-1 (GLP-1)模拟物exendin-4治疗75天的大鼠出现了低度胰腺炎。一个明显的问题是,低级别胰腺炎是否也存在于使用合成exendin-4(艾塞那肽)或其他基于glp -1的治疗的人类中?Nachnani等人的论文及时地加入了一个日益增长的兴趣和争议领域,目前,问题多于答案。
In the present edition of Diabetologia, Nachnani and colleagues report that rats treated with the glucagon-likepeptide-1 (GLP-1) mimetic, exendin-4, for 75 days developed low-grade pancreatitis [1]. The obvious question is whether low-grade pancreatitis is also present in humans treated with synthetic exendin-4 (exenatide) or other GLP-1-based therapies? The paper by Nachnani et al. is a timely addition to an area of growing interest and controversy in which, at present, there are more questions than answers.
DOI: 10.1007/s00125-009-1515-4
发表时间: 2010-01-01
期刊: DIABETOLOGIA
影响因子: 8.2
作者:
Nachnani, J. S.;Bulchandani, D. G.;Alba, L. M.
通讯作者: Alba, L. M.
DOI: 10.1007/s00125-009-1556-8
发表时间: 2010-01
期刊: DIABETOLOGIA
影响因子: 8.2
作者:
Butler, A. E.;Galasso, R.;Matveyenko, A.;Rizza, R. A.;Dry, S.;Butler, P. C.
通讯作者: Butler, P. C.
DOI: 10.2337/db09-0058
发表时间: 2009-07
期刊: Diabetes
影响因子: 7.7
作者:
Matveyenko AV;Dry S;Cox HI;Moshtaghian A;Gurlo T;Galasso R;Butler AE;Butler PC
通讯作者: Butler PC
DOI: 10.1038/23716
发表时间: 1999-08-26
期刊: NATURE
影响因子: 64.8
作者:
Apelqvist, Å;Li, H;Edlund, H
通讯作者: Edlund, H
DOI: 10.1185/03007990902820519
发表时间: 2009-04-01
影响因子: 2.3
作者:
Dore, David D.;Seeger, John D.;Chan, K. Arnold
通讯作者: Chan, K. Arnold